TY - CHAP M1 - Book, Section TI - Soft Tissue Sarcomas A1 - Gonzalez, Ricardo J. A1 - Gronchi, Alessandro A1 - Pollock, Raphael E. A2 - Brunicardi, F. Charles A2 - Andersen, Dana K. A2 - Billiar, Timothy R. A2 - Dunn, David L. A2 - Kao, Lillian S. A2 - Hunter, John G. A2 - Matthews, Jeffrey B. A2 - Pollock, Raphael E. PY - 2019 T2 - Schwartz's Principles of Surgery, 11e AB - Key Points Sarcomas are a heterogeneous group of tumors that can occur throughout the body and encompass more than 50 subtypes with distinct histologic lines of differentiation. Approximately two-thirds of soft tissue sarcomas arise in the extremities; the remaining one-third is distributed between the retroperitoneum, trunk, abdomen, head, and neck. Multimodality treatment, including surgical resection, radiation therapy, and, in selected cases, systemic chemotherapy, has been applied to patients with locally advanced, high-grade, extremity sarcomas. Overall 5-year survival rate for patients with all stages of soft tissue sarcoma is 50% to 60%. These rare tumors account for less than 1% of cancer in adults (estimated 10,000 cases per year in the United States) and represent 15% of cancers in children. The treatment algorithm for soft tissue sarcomas depends on tumor stage, site, and histology. Of the patients who die of sarcoma, most will succumb to metastatic disease in the lungs, which 80% of the time occurs within 2 to 3 years of the initial diagnosis. Progress in the understanding of soft tissue sarcoma biology is crucial for the development of new treatments. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1175971385 ER -